Nifty
Sensex
:
:
14622.40
49431.00
-474.95 (-3.15%)
-1608.31 (-3.15%)

Pharmaceuticals & Drugs - API

Rating :
65/99

BSE: 524348 | NSE: AARTIDRUGS

635.55
25-Feb-2021
  • Open
  • High
  • Low
  • Previous Close
  •  640.00
  •  643.35
  •  634.55
  •  634.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  202903
  •  1293.27
  •  1026.95
  •  105.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,923.79
  • 20.59
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,295.03
  • 0.08%
  • 6.70

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.20%
  • 1.03%
  • 31.78%
  • FII
  • DII
  • Others
  • 3.06%
  • 1.52%
  • 2.41%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.68
  • 9.64
  • 13.24

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.40
  • 8.11
  • 5.63

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.66
  • 15.52
  • 19.77

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.76
  • 16.49
  • 15.52

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.66
  • 3.58
  • 3.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.52
  • 10.38
  • 10.71

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
530.25
473.51
11.98%
578.11
477.50
21.07%
544.67
405.43
34.34%
449.64
459.14
-2.07%
Expenses
424.49
406.02
4.55%
461.67
409.20
12.82%
410.70
350.71
17.11%
378.33
403.23
-6.18%
EBITDA
105.76
67.49
56.70%
116.44
68.30
70.48%
133.97
54.72
144.83%
71.31
55.91
27.54%
EBIDTM
19.95%
14.25%
20.14%
14.30%
24.60%
13.50%
15.86%
12.18%
Other Income
2.00
0.25
700.00%
0.29
0.19
52.63%
1.26
0.06
2,000.00%
0.98
1.22
-19.67%
Interest
4.97
8.39
-40.76%
7.05
8.54
-17.45%
6.57
9.33
-29.58%
7.47
10.34
-27.76%
Depreciation
12.65
12.36
2.35%
12.56
12.09
3.89%
12.38
11.81
4.83%
12.49
10.81
15.54%
PBT
90.36
43.08
109.75%
97.12
47.86
102.93%
116.28
33.64
245.66%
60.71
39.75
52.73%
Tax
22.33
15.30
45.95%
21.85
15.55
40.51%
30.83
11.18
175.76%
1.85
12.31
-84.97%
PAT
68.03
27.78
144.89%
75.27
32.31
132.96%
85.45
22.46
280.45%
58.86
27.44
114.50%
PATM
12.83%
5.87%
13.02%
6.77%
15.69%
5.54%
13.09%
5.98%
EPS
7.30
2.98
144.97%
8.08
3.47
132.85%
9.17
2.41
280.50%
6.32
2.91
117.18%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
2,102.67
1,806.09
1,560.94
1,243.63
1,195.17
1,139.84
1,096.88
501.05
478.50
382.12
312.36
Net Sales Growth
15.81%
15.71%
25.51%
4.05%
4.85%
3.92%
118.92%
4.71%
25.22%
22.33%
 
Cost Of Goods Sold
1,284.64
1,127.29
1,013.53
737.72
744.43
735.08
724.24
321.34
301.35
238.85
197.35
Gross Profit
818.03
678.79
547.40
505.91
450.75
404.77
372.65
179.71
177.15
143.27
115.01
GP Margin
38.90%
37.58%
35.07%
40.68%
37.71%
35.51%
33.97%
35.87%
37.02%
37.49%
36.82%
Total Expenditure
1,675.19
1,540.57
1,350.03
1,041.76
1,004.68
960.02
924.51
431.87
396.04
315.67
266.61
Power & Fuel Cost
-
103.83
84.39
71.42
59.42
53.93
49.56
29.07
26.48
23.27
19.70
% Of Sales
-
5.75%
5.41%
5.74%
4.97%
4.73%
4.52%
5.80%
5.53%
6.09%
6.31%
Employee Cost
-
61.35
54.55
52.14
47.95
40.19
33.26
19.93
14.77
12.00
10.54
% Of Sales
-
3.40%
3.49%
4.19%
4.01%
3.53%
3.03%
3.98%
3.09%
3.14%
3.37%
Manufacturing Exp.
-
160.38
142.69
130.01
103.21
87.60
75.53
39.18
32.32
25.17
24.22
% Of Sales
-
8.88%
9.14%
10.45%
8.64%
7.69%
6.89%
7.82%
6.75%
6.59%
7.75%
General & Admin Exp.
-
21.39
14.24
12.22
12.81
10.98
10.48
4.86
4.95
3.80
3.14
% Of Sales
-
1.18%
0.91%
0.98%
1.07%
0.96%
0.96%
0.97%
1.03%
0.99%
1.01%
Selling & Distn. Exp.
-
59.46
37.51
34.00
31.16
27.82
28.99
16.21
14.47
11.69
9.99
% Of Sales
-
3.29%
2.40%
2.73%
2.61%
2.44%
2.64%
3.24%
3.02%
3.06%
3.20%
Miscellaneous Exp.
-
6.88
3.11
4.24
5.71
4.42
2.45
1.27
1.71
0.89
9.99
% Of Sales
-
0.38%
0.20%
0.34%
0.48%
0.39%
0.22%
0.25%
0.36%
0.23%
0.53%
EBITDA
427.48
265.52
210.91
201.87
190.49
179.82
172.37
69.18
82.46
66.45
45.75
EBITDA Margin
20.33%
14.70%
13.51%
16.23%
15.94%
15.78%
15.71%
13.81%
17.23%
17.39%
14.65%
Other Income
4.53
1.48
2.41
1.05
4.00
0.00
0.65
0.16
0.63
0.52
1.85
Interest
26.06
37.42
43.51
38.36
40.02
48.02
42.28
17.12
18.66
26.45
14.48
Depreciation
50.08
48.75
42.56
40.06
38.46
36.53
31.02
19.11
17.03
14.48
13.02
PBT
364.47
180.82
127.26
124.50
116.01
95.27
99.72
33.11
47.40
26.04
20.09
Tax
76.86
43.89
41.27
42.20
34.21
26.55
22.47
9.61
18.96
8.47
5.28
Tax Rate
21.09%
23.69%
31.50%
33.90%
29.49%
27.87%
22.53%
29.02%
40.00%
32.53%
26.28%
PAT
287.61
141.40
89.75
82.31
81.80
68.72
77.25
23.50
28.06
16.71
14.08
PAT before Minority Interest
287.62
141.40
89.75
82.31
81.80
68.72
77.25
23.50
28.44
17.57
14.81
Minority Interest
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-0.38
-0.86
-0.73
PAT Margin
13.68%
7.83%
5.75%
6.62%
6.84%
6.03%
7.04%
4.69%
5.86%
4.37%
4.51%
PAT Growth
161.49%
57.55%
9.04%
0.62%
19.03%
-11.04%
228.72%
-16.25%
67.92%
18.68%
 
EPS
30.86
15.17
9.63
8.83
8.78
7.37
8.29
2.52
3.01
1.79
1.51

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
652.49
543.45
455.43
400.13
357.40
308.15
163.16
146.45
123.45
111.53
Share Capital
23.30
23.58
23.58
23.86
24.22
24.22
12.11
12.11
11.71
11.71
Total Reserves
629.19
519.86
431.85
376.27
333.18
283.94
151.05
134.34
111.53
99.82
Non-Current Liabilities
299.31
321.06
312.31
296.59
243.78
211.03
290.20
209.85
210.70
233.12
Secured Loans
171.74
199.64
190.53
187.38
176.66
152.72
204.83
138.66
160.86
127.57
Unsecured Loans
8.57
8.57
12.17
14.17
14.57
10.75
62.65
50.16
31.35
89.58
Long Term Provisions
23.63
12.32
16.87
8.39
1.42
0.29
0.00
0.00
0.00
0.00
Current Liabilities
624.70
590.98
621.68
494.31
501.02
482.76
70.10
57.99
59.62
57.40
Trade Payables
329.55
242.63
258.73
196.97
184.90
166.72
65.30
50.18
54.78
54.50
Other Current Liabilities
132.83
82.94
56.42
51.00
43.80
41.53
1.77
1.68
1.33
0.80
Short Term Borrowings
157.73
263.25
305.64
244.66
258.41
252.43
0.00
0.00
0.00
0.00
Short Term Provisions
4.59
2.16
0.89
1.68
13.91
22.08
3.03
6.13
3.51
2.11
Total Liabilities
1,576.50
1,455.49
1,389.42
1,191.03
1,102.20
1,001.94
523.46
419.15
403.24
416.63
Net Block
643.81
624.86
602.39
581.09
493.42
448.46
247.84
208.20
205.24
189.94
Gross Block
1,030.97
970.09
909.20
848.13
725.47
685.21
393.33
332.42
309.85
277.70
Accumulated Depreciation
387.16
345.22
306.81
267.04
232.05
236.75
145.49
124.21
104.61
87.76
Non Current Assets
672.50
671.20
652.55
619.61
536.97
476.40
263.50
213.35
207.43
217.81
Capital Work in Progress
12.21
32.75
28.45
14.28
34.04
16.06
10.37
3.40
0.64
14.67
Non Current Investment
13.36
12.44
10.76
11.94
4.63
4.63
5.28
1.74
1.55
13.20
Long Term Loans & Adv.
3.12
1.15
10.95
12.30
4.88
7.24
0.00
0.00
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
904.00
784.29
736.86
571.42
565.23
525.54
259.96
205.81
195.80
198.80
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
325.40
246.61
278.21
209.63
178.35
164.20
91.83
64.41
60.52
66.21
Sundry Debtors
488.63
458.54
374.94
296.81
331.69
314.27
121.34
115.87
113.48
103.29
Cash & Bank
7.64
5.55
4.27
4.17
4.82
3.58
5.27
8.52
3.48
4.02
Other Current Assets
82.32
6.56
10.21
0.00
50.37
43.49
41.52
17.01
18.32
25.27
Short Term Loans & Adv.
75.50
67.02
69.23
60.81
50.37
43.49
40.62
16.01
17.52
24.49
Net Current Assets
279.30
193.31
115.19
77.11
64.20
42.78
189.86
147.82
136.18
141.39
Total Assets
1,576.50
1,455.49
1,389.41
1,191.03
1,102.20
1,001.94
523.46
419.16
403.23
416.65

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
250.74
143.09
69.77
174.75
133.29
104.59
20.56
59.12
64.90
28.39
PBT
185.29
131.02
124.50
116.01
95.27
99.72
33.11
47.40
26.04
20.09
Adjustment
86.84
75.20
75.12
71.63
79.30
69.40
38.76
38.77
41.71
27.51
Changes in Working Capital
19.49
-33.49
-105.19
8.47
-21.25
-49.58
-40.22
-13.27
2.39
-15.17
Cash after chg. in Working capital
291.62
172.74
94.44
196.11
153.33
119.53
31.65
72.90
70.14
32.43
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-40.88
-29.64
-24.67
-21.36
-20.03
-14.94
-11.09
-13.80
-5.24
-4.05
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-33.21
-61.67
-73.54
-106.98
-98.79
-107.01
-76.36
-30.46
-11.51
-33.16
Net Fixed Assets
-49.10
-62.81
-72.64
-92.88
-46.34
-322.27
-65.29
-22.98
-19.64
-21.98
Net Investments
-1.46
-1.68
1.18
-7.30
-0.01
13.50
-3.23
0.00
12.15
-12.18
Others
17.35
2.82
-2.08
-6.80
-52.44
201.76
-7.84
-7.48
-4.02
1.00
Cash from Financing Activity
-215.41
-80.07
3.92
-68.23
-33.26
1.46
52.55
-23.62
-53.92
3.61
Net Cash Inflow / Outflow
2.13
1.35
0.15
-0.45
1.24
-0.95
-3.25
5.04
-0.53
-1.16
Opening Cash & Equivalents
4.64
3.29
3.15
3.60
3.58
4.53
8.52
3.48
4.02
5.18
Closing Cash & Equivalent
6.77
4.64
3.29
3.15
4.82
3.58
5.27
8.52
3.49
4.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
70.01
57.61
193.12
167.72
147.58
127.25
67.37
60.47
52.63
47.61
ROA
9.33%
6.31%
6.38%
7.13%
6.53%
10.13%
4.99%
6.92%
4.29%
3.78%
ROE
23.65%
17.97%
19.24%
21.60%
20.65%
32.78%
15.18%
21.09%
14.97%
14.08%
ROCE
21.39%
17.01%
17.31%
18.50%
18.33%
23.93%
13.12%
20.30%
16.30%
11.03%
Fixed Asset Turnover
1.81
1.66
1.44
1.64
1.75
2.19
1.45
1.57
1.42
1.26
Receivable days
95.71
97.45
97.10
89.05
95.59
67.25
82.06
83.04
95.17
98.73
Inventory Days
57.80
61.36
70.52
54.97
50.69
39.52
54.05
45.23
55.64
69.71
Payable days
64.68
68.08
73.82
67.66
65.68
45.51
45.97
46.92
62.87
59.81
Cash Conversion Cycle
88.83
90.73
93.79
76.36
80.60
61.26
90.14
81.35
87.94
108.62
Total Debt/Equity
0.58
0.93
1.20
1.20
1.26
1.45
1.64
1.29
1.56
1.95
Interest Cover
5.95
4.01
4.25
3.90
2.98
3.36
2.93
3.54
1.98
2.39

News Update:


  • Aarti Drugs closes subsidiary company
    20th Feb 2021, 10:04 AM

    The wounding-up of this subsidiary will not affect the revenue or business of the company due to nil business activity of this subsidiary

    Read More
  • Aarti Drugs reports over 2-fold jump in Q3 consolidated net profit
    27th Jan 2021, 10:34 AM

    Total consolidated income of the company increased by 12.35% at Rs 532.26 crore for Q3FY21

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.